A Phase 2 interventional study of Low dose antigen of LYB005 without A01B adjuvant and Low dose antigen of LYB005 with A01B adjuvant in Respiratory Syncytial Virus Infection Prevention, sponsored by Guangzhou Patronus Biotech Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Guangzhou Patronus Biotech Co., Ltd. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.
Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2025, is one of 6 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 24th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:
Ab&B Bio-tech Co., Ltd.JS · Sites in China
Ages 18+ · Healthy volunteers
Simcere Pharmaceutical Co., Ltd · Sites in China
Ages 1 mo–36 mo
Shanghai Ark Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–85
Kexing Biopharm Co., Ltd. · Sites in China
Ages 2 mo–2 yrs
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–45 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 10
First in 2019; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 700 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 132 across the 25 interventional studies, 816 across the 5 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 30 have an industry lead sponsor. The 10 most frequent:
Guangzhou Patronus Biotech Co., Ltd. is the lead sponsor of 15 studies on the registry; 4 are open to participants now.
Guangzhou Patronus Biotech Co., Ltd. has 3 studies filed under Respiratory Syncytial Virus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Respiratory Syncytial Virus Infections with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07402512Phase 3Simcere Pharmaceutical Co., LtdA Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children | 2027-03-31 |
| NCT06363370Phase 3Kexing Biopharm Co., Ltd.Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections | 2027-06-30 |
| NCT06645665Shenzhen Shenxin Biotechnology Co., LtdA Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above | 2027-04 |
| NCT07582796Ab&B Bio-tech Co., Ltd.JSClinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. | 2027-09-14 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, observer-blinded, placebo-controlled Phase Ⅱ clinical trial to evaluate the immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.
A randomized, observer-blinded, placebo-controlled trial will be conducted to observe the immunogenicity and safety of LYB005 in adults aged 60 years and older. A total of 700 participants aged 60 years and older will be enrolled. Six formulations of LYB005 will be provided, three dose levels of antigen with or without A01B adjuvant. All participants will randomly receive six investigational vaccines and the placebo in a 1:1:1:1:1:1:1 ratio.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (low dose antigen without A01B adjuvant) at Day 0.
Biological: Low dose antigen of LYB005 without A01B adjuvant
Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (low dose antigen with A01B adjuvant) at Day 0.
Biological: Low dose antigen of LYB005 with A01B adjuvant
Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (middle dose antigen without A01B adjuvant) at Day 0.
Biological: Middle dose antigen of LYB005 without A01B adjuvant
Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (middle dose antigen with A01B adjuvant) at Day 0.
Biological: Middle dose antigen of LYB005 with A01B adjuvant
Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (high dose antigen without A01B adjuvant) at Day 0.
Biological: High dose antigen of LYB005 without A01B adjuvant
Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (high dose antigen with A01B adjuvant) at Day 0.
Biological: High dose antigen of LYB005 with A01B adjuvant
Participants aged 60 years and older will be vaccinated with 1 dose of placebo at Day 0.
Biological: Placebo
0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.
0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.
0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.
0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.
0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.
0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.
0.5 mL 0.9% sodium chloride (normal saline) injection per dose
The geometric mean titer (GMT) of Neutralizing Antibodies Against RSV A and RSV B
Measured by microneutralization assay.
Time frame: 30 days after vaccination
Geometric Mean Fold Rise (GMFR) for Neutralizing Antibodies Against RSV A and RSV B
Change from prevaccination in geometric mean fold rise of Neutralizing antibody titer Against RSV A and RSV B
Time frame: 30 days after vaccination
The GMT of Neutralizing Antibodies Against RSV A and RSV B
Measured by microneutralization assay.
Time frame: 14 days, 3 months, 6 months and 12 months after vaccination after vaccination
GMFR for Neutralizing Antibodies Against RSV A and RSV B
Change from prevaccination in geometric mean fold rise of Neutralizing antibody titer Against RSV A and RSV B
Time frame: 14 days, 3 months, 6 months and 12 months after vaccination
The geometric mean concentration (GMC) for Pre-fusion Protein Specific Binding Antibodies
Measured by Enzyme-Linked Immunosorbent Assay (ELISA).
Time frame: 30 days, 3 months, 6 months and 12 months after vaccination
GMFR for Pre-fusion Protein Specific Binding Antibodies
Change from prevaccination in geometric mean fold rise of Pre-fusion Protein Specific Binding Antibodies
Time frame: 30 days, 3 months, 6 months and 12 months after vaccination
Occurrence of immediate adverse events
The incidence and severity of any adverse events (AEs) within 30 minutes after vaccination
Time frame: Within 30 minutes after vaccination
Incidence of solicited AE
Occurrence and severity of solicited local injection site reactions for 7 days (Day 0-Day 7) following vaccination. (i.e., pain, redness, swelling). Occurrence and severity of solicited systemic reactions for 7 days (Day 0-Day 7) following vaccination. (i.e., myalgia, fatigue, headache, chills, fever).
Time frame: Within 0-7 days after vaccination
Incidence of unsolicited AEs
The incidence and severity of any unsolicited AEs, including all AEs, except solicited AEs reported Day 0\~30 after the vaccination.
Time frame: Within 0~30 days after vaccination
Occurrence of serious adverse events (SAEs) and adverse events of special interests (AESIs)
Incidence and severity of Serious adverse events and adverse events of special interest within 12 months after vaccination.
Time frame: 12 months after vaccination
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Mar 2026, 5 months after the start.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 5 months is below that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Syncytial Virus Infections →
Guangzhou Patronus Biotech Co., Ltd.